南财智讯12月1日电，金迪克公告，公司董事会于近日收到证券事务代表谭华海先生提交的书面辞职报 告，谭华海先生因个人原因申请辞去公司证券事务代表职务，辞职后不再担任公司任何职务。谭华海先 生的辞职报告自送达董事会之日起生效。 ...

Core Insights - The flu activity in China is rapidly increasing, with the proportion of flu-like cases in southern provinces reaching 6.7% and northern provinces as high as 12%, significantly above previous years' levels [1] - The current flu outbreak is primarily driven by the H3N2 subtype, with a notable increase in demand for antiviral medications such as Oseltamivir and Baloxavir, leading to a surge in sales [1][2] - Domestic pharmaceutical companies, including Notai Bio, Kangyuan Pharmaceutical, and Jindike, are gaining market attention due to their antiviral product offerings and technological advancements [2][4] Industry Trends - The demand for flu medications has led to stock shortages in pharmacies, particularly for original research drugs [2] - Notai Bio has positioned itself competitively in the Oseltamivir market, with multiple drug registration certificates and an organized production line to meet the rising demand [2][3] - The market is transitioning from a dominance of Oseltamivir to a more diversified landscape with both traditional and innovative antiviral drugs being introduced [5] Company Highlights - Notai Bio has achieved significant sales growth for its Oseltamivir capsules, surpassing imported alternatives and establishing a strong online presence [3] - Kangyuan Pharmaceutical's products, such as the anti-viral injection and oral liquid, have shown resilience in sales despite overall revenue declines, indicating a strong growth potential in the flu season [4] - Jindike focuses on flu prevention with its quadrivalent flu vaccine, which has a production capacity of 20 million doses annually and is included in the national immunization program [4][5]

Group 1 - The flu activity in China is rapidly increasing, with sentinel hospitals in southern provinces reporting flu-like cases at 6.7%, up from 5.5% the previous week, and northern provinces reaching 12%, significantly higher than the same period from 2020 to 2023 [1] - The current flu strains include the H3N2 subtype, Victoria lineage, and H1N1, with significant antigenic variation leading to increased susceptibility in the population [1] - The demand for antiviral medications has surged, with sales of Oseltamivir increasing by 237% and Baloxavir by 180%, indicating a doubling of orders for flu-specific medications on platforms like Meituan and JD Health [1][2] Group 2 - Domestic pharmaceutical companies such as Nuotai Bio, Kangyuan Pharmaceutical, and Jindike are accelerating their entry into the flu treatment market, focusing on antiviral products [2] - Nuotai Bio has established itself as a competitive player in the Oseltamivir market, actively organizing production to ensure supply amid rising demand [2][3] - Kangyuan Pharmaceutical's products, including the antiviral injection and oral solution, have seen increased sales, with the oral solution contributing significantly to the company's revenue [4] Group 3 - The market is shifting from a dominance of Oseltamivir to a new phase where traditional and innovative treatments coexist, with new drugs like Marzula and Angladi being approved [5] - Companies with differentiated advantages and stable supply chains are expected to stand out in this competitive landscape, particularly those like Nuotai Bio that are deeply embedded in the global antiviral drug supply chain [5] - The upcoming flu peak is creating new growth opportunities for domestic pharmaceutical companies, driven by the increased demand for flu medications [5]

中国经济网北京11月28日讯 金迪克(688670.SH)今日收报27.40元，跌幅6.55%，总市值33.76亿元。 金迪克首次公开发行股票募集资金总额为12.14亿元，募集资金净额11.36亿元，较原拟募资净额少 4.64亿元。金迪克此前披露的招股书显示，该公司原拟募资16亿元，分别用于新建新型四价流感病毒裂 解疫苗车间建设项目、创新疫苗研发项目、补充流动资金及偿还银行借款项目。 金迪克于2021年8月2日在上交所科创板上市，公开发行新股2200万股，发行价格55.18元/股，保荐 机构为中信证券，保荐代表人为周游、赵岩。目前该股处于破发状态。 2023年5月19日，金迪克发布2022年年度权益分派实施公告。本次利润分配及转增股本以方案实施 前的公司总股本88,000,000股为基数，每股派发现金红利0.2元（含税），以资本公积金向全体股东每股 转增0.4股，共计派发现金红利17,600,000.00元，转增35,200,000股，本次分配后总股本为123,200,000 股。金迪克股权登记日2023年5月25日，除权（息）日2023年5月26日，新增无限售条件流通股份上市日 2023年5月26日，现金红 ...

Core Viewpoint - The market experienced mixed performance with the ChiNext index closing down 0.44%, while the influenza and organic silicon sectors surged, indicating a divergence in market sentiment driven by specific sectoral developments [1][4]. Group 1: Influenza Sector - The influenza sector saw a significant uptick, with flu-like cases in northern provinces rising to 7.0%, markedly higher than the same period in previous years [4]. - Sales of antiviral drugs, such as Oseltamivir, surged by 237% over the past week, indicating strong demand driven by rising flu cases [4]. - Jindike has completed the production season with 1.56 million doses of its quadrivalent flu vaccine approved for release, and is ramping up production capacity to 30 million doses [4]. Group 2: Organic Silicon Sector - The organic silicon sector experienced a boost following Dow Chemical's announcement of a 10%-20% price increase on major products starting December 10, which acted as a catalyst for domestic stocks [4]. - Companies like Hongbai New Materials and Chenguang New Materials saw their stocks hit the daily limit, while Dongyue Silicon Material rose over 10% [4]. - Smart money has already positioned itself in this sector, with Chenguang New Materials seeing a net inflow of 85.14 million yuan over the past ten trading days [4]. Group 3: Underperforming Sectors - The Hainan sector faced significant declines, with companies like Jingliang Holdings and Hainan Haiyao dropping nearly 7%, highlighting the lack of performance support for regional themes [4]. - The film and content industry also struggled, with Huanrui Century hitting the daily limit down and Shanghai Film falling nearly 7%, reflecting uncertainty in the content sector [4]. Group 4: Market Sentiment and Strategy - The overall trading volume decreased by 93.5 billion yuan compared to the previous day, indicating a cautious market sentiment and a tendency for rapid sector rotation [4]. - Investment strategies suggest focusing on the influenza sector for low-entry opportunities and the organic silicon sector for potential gains, while avoiding sectors lacking performance, policy support, or growth potential [5].

Market Overview - On November 26, the Shanghai Composite Index fell by 0.15%, while the total margin balance in the market reached 24,693.55 billion yuan, an increase of 6.32 billion yuan compared to the previous trading day [1] - The margin balance in the Shanghai Stock Exchange was 12,542.51 billion yuan, up by 2.67 billion yuan; in the Shenzhen Stock Exchange, it was 12,076.25 billion yuan, increasing by 3.67 billion yuan; the North Exchange saw a decrease of 0.15 billion yuan, bringing the total margin balance to 24,693.55 billion yuan [1] Industry Analysis - Among the industries tracked by Shenwan, 20 sectors saw an increase in margin balances, with the electronics sector leading with an increase of 2.86 billion yuan, followed by the communication and power equipment sectors with increases of 2.57 billion yuan and 1.36 billion yuan, respectively [1] Stock Performance - A total of 1,768 stocks experienced an increase in margin balances, accounting for 47.16% of the market, with 200 stocks seeing an increase of over 5% [1] - The stock with the largest increase in margin balance was Sanwei Tiandi, which saw a margin balance of 159 million yuan, an increase of 88.79%, and its stock price rose by 20.01% [1] - Other notable stocks with significant margin balance increases included C Hai'an and Jindike, with increases of 59.28% and 53.80%, respectively [1][2] Top Gainers and Losers - Among the top 20 stocks with the largest margin balance increases, the average increase in stock prices was 3.22%, with Sanwei Tiandi, Jindike, and Pinggao Co. leading with increases of 20.01%, 20.00%, and 18.99%, respectively [2] - Conversely, stocks with the largest declines included Fuchun Co., C Hai'an, and Dadi Ocean, with declines of 11.11%, 4.21%, and 3.06%, respectively [2] Margin Balance Decrease - A total of 1,981 stocks saw a decrease in margin balances, with 155 stocks experiencing a decline of over 5% [4] - The stock with the largest decrease in margin balance was Aerospace Development, which saw a margin balance of 831.26 million yuan, a decrease of 32.13% [4][5] - Other stocks with significant declines included Xueqi Electric and Shengjing Micro, with decreases of 31.67% and 30.84%, respectively [4][5]

Company Movements - China International Capital Corporation (CICC) is planning to absorb and merge Dongxing Securities and Xinda Securities through a share swap, involving both A and H shares, leading to a complex process with A shares currently suspended from trading [5] - Industrial Fulian has adjusted the upper limit for its share repurchase price from 19.36 yuan per share to 75 yuan per share [6] - ByteDance responded to media reports claiming that its Tomato series businesses would generate over 30 billion yuan in revenue and profits of 3 to 5 billion yuan, stating that the figures are inaccurate [6] - Ideal Auto reported third-quarter revenue of 27.4 billion yuan with a net loss of 360.3 million yuan, and a year-on-year decline in vehicle deliveries by 39% [6] Investment News - On November 26, the A-share market experienced a pullback, with the Shanghai Composite Index closing down 0.15% at 3864.18 points, while the Shenzhen Component Index rose by 1.02% and the ChiNext Index increased by 2.14%, with total market turnover reaching 1.8 trillion yuan [4] - Insurance funds are seeing new capital entering the market as Sunshine and Yuan Private Securities Investment Fund have been registered with the Asset Management Association of China, marking the 10th fund to officially begin operations [4] - The trial for optimizing brokerage account management functions has expanded for the first time in nearly three years, with eight brokerages including Guolian Minsheng and Huaxin Securities now qualified, bringing the total to 20 [4] - Southbound capital has significantly increased its investment in Hong Kong stocks, with a cumulative net purchase of 1.38 trillion Hong Kong dollars this year, the highest on record, contributing to a nearly 30% rise in the Hang Seng Index [4]

Industry News - The China Insurance Industry Association issued a risk warning regarding the "Anwo Stock Insurance" business, stating that it is not an approved insurance product and that stock investment losses are not insurable. The platform's activities may involve illegal financial operations [6]. - Beijing's Internet Information Office and the Beijing Financial Regulatory Bureau launched a three-month campaign to address six types of online financial misconduct, focusing on misleading public information and illegal financial services [7]. - The Ministry of Industry and Information Technology and five other departments released a plan to enhance the adaptability of supply and demand for consumer goods, aiming for a significant optimization of the supply structure by 2027, with three trillion-level consumption sectors and ten hundred-billion-level consumption hotspots [7]. - The Ministry of Natural Resources announced breakthroughs in the efficient extraction of low-grade rare metals from coal, aluminum, copper, lead, and zinc ores, with significant improvements in recovery rates for various metals [7]. - The first hydrogen refueling station in China utilizing underground hydrogen storage technology has been operational for over 1500 days, supplying over 400 tons of hydrogen, marking a significant advancement in high-pressure underground hydrogen storage technology [8]. Company News - Dongwei Technology announced a significant increase in PCB plating equipment orders, driven by rapid growth in the PCB and memory sectors, with expected record-high order amounts this year [11]. - North University Pharmaceutical stated that related flu medications have not yet been produced or sold, and this will not impact the company's performance for a considerable time [12]. - *ST Dongtong disclosed that its annual reports from 2019 to 2022 contained false records and has received a notice of termination of listing [13]. - Debang Technology's largest shareholder, the National Big Fund, reduced its stake by 2% between September 11 and October 16, completing its reduction plan [13]. - Muxi Co., Ltd. plans to issue 40.1 million shares, with the initial strategic placement of 8.02 million shares, and the subscription date set for December 5, 2025 [15].

Group 1 - The Ministry of Commerce of China and the European Commission discussed semiconductor supply chain issues, emphasizing the need for constructive communication between ASML Netherlands and ASML China to stabilize the global semiconductor supply chain [2] - Vanke faced a significant decline in both stock and bond markets, with some bonds dropping over 35% and the stock price nearing historical lows, prompting a meeting regarding bond extension [2] - The Chinese government instructed domestic airlines to reduce flights to Japan before March 2026, reflecting ongoing diplomatic tensions [3] Group 2 - Six departments in China released a plan to enhance the adaptability of consumer goods supply and demand, aiming for a significant optimization of the supply structure by 2027 [3] - The National Development and Reform Commission announced a new management method for credit repair, effective from April 2026, categorizing dishonest information into three levels [3] - The A-share market saw fluctuations, with the Shanghai Composite Index closing down 0.15%, while the Shenzhen Component Index and the ChiNext Index recorded gains [4] Group 3 - Li Auto reported a 36.2% year-on-year decline in Q3 revenue, with an adjusted net loss of 360 million yuan, and projected a further decline in Q4 revenue [5] - The insurance sector welcomed new funds into long-term investment trials, with a new private equity fund entering operation [4] - The Chinese Nonferrous Metals Industry Association opposed the zero or negative processing fees in the copper smelting industry, calling for better management of copper smelting capacity [8] Group 4 - The medical device market in China is expected to reach 1.22 trillion yuan by 2025, with a significant increase in the number of production enterprises [9] - The financial support plan in Guangdong aims to facilitate industry chain integration and improve the quality of listed companies [8] - The Hong Kong stock market saw a net sell-off of 39.52 billion HKD by southbound funds, with notable movements in major tech stocks [4]

目前，各类流感药品销售已经出现增长。根据叮当快药数据，奥司他韦和速福达（玛巴洛沙韦）销量上 升比较明显，奥司他韦近七天销量增长237%，玛巴洛沙韦上涨180%。同时一些感冒退热、清热解毒、 止咳平喘以及鼻喷类的药物销量均有上涨。 国家流感中心披露的《中国流感监测周报》显示，11月10日至11月16日南、北方省份流感活动上升。其 中北方省份哨点医院报告的ILI%（流感样病例百分比）为7.0%，不仅高于前一周水平（6.2%），也高 于2022年、2023年和2024年同期水平（2.1%、5.8%和3.9%）。同时，日本、英国等地流感疫情持续， 活动性也高于往年同期水平。 近期，多家上市公司积极行动，应对流感季的到来。圣湘生物与阿里健康围绕呼吸道感染性疾病领域达 成合作，结合淘宝闪购推出"居家闪检"服务；精华制药布局有玛巴洛沙韦等产品，公司称将根据市场情 况适时调整生产节奏，保证市场供应；康缘药业抗感染和呼吸领域核心产品，在流感季节需求有显著增 长，公司正在加紧排产来满足日益增长的需求。 健康元在25日披露了公司进度最靠前的治疗流感的创新药玛帕西沙韦胶囊的进展，目前该产品已进入审 评后期，公司正积极推进商业化准备工 ...